- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
BillionToOne, Inc. Class A Common Stock(BLLN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BLLN
11/13/2026: BLLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
BillionToOne is a commercial-stage molecular diagnostics company that develops high-resolution prenatal screening and oncology liquid biopsy tests using its proprietary QCT platform. The company's main strengths include rapid revenue growth, solid gross margins, and strong adoption of its flagship UNITY prenatal screening suite. Its primary investment story centers on scaling its oncology portfolio and expanding health system integrations to capture broader market share. Key risks involve intense competition from larger diagnostics peers, potential reimbursement headwinds, and execution challenges in scaling new assays. The stock suits growth-oriented investors willing to navigate short-term volatility while monitoring quarterly test volume expansion and new product adoption milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Rapid top-line expansion and large addressable markets align well with growth mandates. |
| Momentum investor | Strong fit while signal remains positive | High trading volume and strong analyst sentiment create favorable conditions during uptrends. |
| Value investor | Weak fit | Trading at high growth-adjusted multiples leaves little margin of safety for traditional value parameters. |
| Dividend investor | Weak fit | The company retains all earnings to fund research and expansion, paying no dividends. |
| Low-risk investor | Weak fit | Clinical development uncertainties and growth stock volatility expose risk-averse holders to drawdowns. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Growth-stage diagnostics stocks experience sharp price swings based on market sentiment and earnings reports. |
| Valuation risk | Medium / high | Priced for perfection, any growth deceleration or earnings miss can trigger multiple compression. |
| Competition risk (Natera and Guardant Health) | High | Intense competition from well-capitalized laboratory peers can pressure pricing and market share gains. |
| Business quality | Strong | Proprietary QCT technology delivers high gross margins and differentiated product utility. |
| Dividend income | Low / none | No dividend is distributed, making total return entirely dependent on stock price appreciation. |
| Execution risk | Medium / high | Successful scaling of oncology sales and EHR integration channels is critical to meeting long-term targets. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.02B USD | Price to earnings Ratio 114.29 | 1Y Target Price 128.29 |
Price to earnings Ratio 114.29 | 1Y Target Price 128.29 | ||
Volume (30-day avg) 596.7K shares | Beta - | 52 Weeks Range 61.96 - 150.44 | Updated Date 11/15/2026 |
52 Weeks Range 61.96 - 150.44 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.92 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -17% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Prenatal Screening Testing | Commercialization of the UNITY portfolio assessing fetal chromosomal and genetic risks from maternal blood draws. | This is the core revenue engine, providing stable, high-margin cash flows from routine obstetrical testing. |
| Oncology Liquid Biopsy | Sales of Northstar Select and Northstar Response panels for cancer therapy selection and disease monitoring. | This segment acts as the primary secondary growth catalyst targeting precision oncology markets. |
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.16 | Actual 0.32 |
Profitability
Profit Margin 10.52% | Operating Margin (TTM) 10.23% |
Management Effectiveness
Return on Assets (TTM) 5.14% | Return on Equity (TTM) 13.23% |
Valuation
Trailing PE 114.29 | Forward PE 64.1 | Enterprise Value 4.60B | Price to Sales(TTM) 11.5 |
Enterprise Value 4.60B | Price to Sales(TTM) 11.5 | ||
Enterprise Value to Revenue 10.54 | Enterprise Value to EBITDA 73.43 | Shares Outstanding 43.27M | Shares Floating 29.34M |
Shares Outstanding 43.27M | Shares Floating 29.34M | ||
Percent Insiders 28.63 | Percent Institutions 48.21 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

